申请人:Merck Sharp & Dohme Ltd.
公开号:US06140347A1
公开(公告)日:2000-10-31
A class of compounds of formula (I) wherein Z, E, Q, T, U, V, W, M, R.sup.1, R.sup.7 and R.sup.8 are as defined herein; are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT.sub.1D.alpha. receptor subtype relative to the 5-HT.sub.1D.beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists. ##STR1##
一类化合物的化学式(I),其中Z,E,Q,T,U,V,W,M,R.sup.1,R.sup.7和R.sup.8的定义如本文所述;它们是5-HT.sub.1样受体的选择性激动剂,是人类5-HT.sub.1Dα受体亚型的有效激动剂,同时相对于5-HT.sub.1Dβ亚型具有至少10倍的选择性亲和力;因此,在治疗和/或预防临床病症方面非常有用,特别是偏头痛及相关疾病,需要5-HT.sub.1D受体亚型选择性激动剂,同时比非亚型选择性5-HT.sub.1D受体激动剂引起更少的副作用,尤其是不良心血管事件。